Daniel L. Levey

906 total citations
17 papers, 709 citations indexed

About

Daniel L. Levey is a scholar working on Immunology, Molecular Biology and Epidemiology. According to data from OpenAlex, Daniel L. Levey has authored 17 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 8 papers in Molecular Biology and 5 papers in Epidemiology. Recurrent topics in Daniel L. Levey's work include Immunotherapy and Immune Responses (10 papers), Heat shock proteins research (6 papers) and Immune Cell Function and Interaction (4 papers). Daniel L. Levey is often cited by papers focused on Immunotherapy and Immune Responses (10 papers), Heat shock proteins research (6 papers) and Immune Cell Function and Interaction (4 papers). Daniel L. Levey collaborates with scholars based in United States, Norway and Japan. Daniel L. Levey's co-authors include Pramod K. Srivastava, Heiichiro Udono, Axel Hoos, Roman M. Chicz, Kenneth LeClair, Cristina Musselli, Sunil Mehta, Jessica B. Flechtner, Brian H. Barber and Anna Wald and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Blood.

In The Last Decade

Daniel L. Levey

17 papers receiving 689 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel L. Levey United States 10 476 381 183 102 98 17 709
Carey L. O’Donnell United States 8 676 1.4× 244 0.6× 345 1.9× 67 0.7× 27 0.3× 12 915
Taketoshi Yamano Japan 7 264 0.6× 354 0.9× 92 0.5× 57 0.6× 101 1.0× 18 471
Daniëlle Horst Netherlands 15 452 0.9× 186 0.5× 371 2.0× 444 4.4× 20 0.2× 17 901
Stephanie Könen‐Waisman Germany 13 311 0.7× 181 0.5× 500 2.7× 21 0.2× 32 0.3× 13 940
Nevil J. Singh United States 16 569 1.2× 148 0.4× 64 0.3× 153 1.5× 12 0.1× 41 778
Yanal Murad Canada 14 209 0.4× 226 0.6× 97 0.5× 166 1.6× 20 0.2× 26 583
Tara L. Chapman United States 8 622 1.3× 93 0.2× 318 1.7× 53 0.5× 19 0.2× 10 788
Christoph Schaefer Switzerland 18 416 0.9× 409 1.1× 119 0.7× 143 1.4× 25 0.3× 30 838
Amy Palin United States 9 242 0.5× 92 0.2× 77 0.4× 54 0.5× 34 0.3× 10 419
Sungae Cho South Korea 8 582 1.2× 260 0.7× 142 0.8× 151 1.5× 24 0.2× 11 897

Countries citing papers authored by Daniel L. Levey

Since Specialization
Citations

This map shows the geographic impact of Daniel L. Levey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel L. Levey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel L. Levey more than expected).

Fields of papers citing papers by Daniel L. Levey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel L. Levey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel L. Levey. The network helps show where Daniel L. Levey may publish in the future.

Co-authorship network of co-authors of Daniel L. Levey

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel L. Levey. A scholar is included among the top collaborators of Daniel L. Levey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel L. Levey. Daniel L. Levey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Levey, Daniel L., Dhan Chand, Margaret K. Wilkens, et al.. (2023). Treatment with doxorubicin and PD-1/CTLA-4 blockade improves T cell activation and anti-tumor efficacy in MCA-205 murine fibrosarcoma. The Journal of Immunology. 210(Supplement_1). 63.18–63.18. 2 indexed citations
2.
3.
Tanne, Antoine, C Galand, Abdo Abou-Slaybi, et al.. (2021). Abstract 1878: Fc-enhanced anti-CTLA-4 antibody, AGEN1181: new mechanistic insights for potent antitumor immunity and combination potential in treatment-resistant solid tumors. Cancer Research. 81(13_Supplement). 1878–1878. 1 indexed citations
4.
Tanne, Antoine, Simarjot Pabla, Sudesh Pawaria, et al.. (2020). Abstract 922: Expanding the therapeutic potential of anti-PD-1 and anti-CTLA-4 therapy with innovative Fc engineering and rationale combinations for the treatment of solid tumors. Cancer Research. 80(16_Supplement). 922–922. 1 indexed citations
5.
Uduman, Mohamed, Kaity Tung, Bjarne Bogen, et al.. (2017). Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model. Blood. 130. 1868–1868. 3 indexed citations
6.
Wald, Anna, David M. Koelle, Kenneth H. Fife, et al.. (2011). Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine. 29(47). 8520–8529. 60 indexed citations
7.
Mo, Annie X., Cristina Musselli, Hong Chen, et al.. (2011). A heat shock protein based polyvalent vaccine targeting HSV-2: CD4+ and CD8+ cellular immunity and protective efficacy. Vaccine. 29(47). 8530–8541. 38 indexed citations
8.
Fuchs, Ephraim J., et al.. (2006). Autologous renal cell cancer vaccines using heat shock protein-peptide complexes. Urologic Oncology Seminars and Original Investigations. 24(5). 425–433. 10 indexed citations
9.
Flechtner, Jessica B., Sunil Mehta, Paul Slusarewicz, et al.. (2006). High-Affinity Interactions between Peptides and Heat Shock Protein 70 Augment CD8+ T Lymphocyte Immune Responses. The Journal of Immunology. 177(2). 1017–1027. 51 indexed citations
10.
Levey, Daniel L., Christian Brander, & Pramod K. Srivastava. (2005). The potential of heat shock protein-peptide complexes as a therapeutic HIV vaccine.. PubMed. 10(3). 56–9. 2 indexed citations
11.
SenGupta, Devi, Philip J. Norris, Todd J. Suscovich, et al.. (2004). Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II. The Journal of Immunology. 173(3). 1987–1993. 63 indexed citations
12.
Hoos, Axel, Daniel L. Levey, & Jera Lewis. (2004). Autologous heat shock protein-peptide complexes for vaccination against cancer: from bench to bedside.. PubMed. 116. 109–15; discussion 133. 5 indexed citations
13.
Hoos, Axel & Daniel L. Levey. (2003). Vaccination with heat shock protein–peptide complexes: from basic science to clinical applications. Expert Review of Vaccines. 2(3). 369–379. 66 indexed citations
14.
Levey, Daniel L., Heiichiro Udono, Michael Heike, & Pramod K. Srivastava. (2001). Identification of a tumor-associated contact-dependent activity which reversibly downregulates cytolytic function of CD8+ T cells.. PubMed. 1. 5–5. 5 indexed citations
15.
Levey, Daniel L. & Pramod K. Srivastava. (1996). Alterations in T cells of cancer-bearers: whence specificity?. Immunology Today. 17(8). 365–368. 55 indexed citations
16.
Levey, Daniel L. & Pramod K. Srivastava. (1995). T cells from late tumor-bearing mice express normal levels of p56lck, p59fyn, ZAP-70, and CD3 zeta despite suppressed cytolytic activity.. The Journal of Experimental Medicine. 182(4). 1029–1036. 39 indexed citations
17.
Udono, Heiichiro, Daniel L. Levey, & Pramod K. Srivastava. (1994). Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo.. Proceedings of the National Academy of Sciences. 91(8). 3077–3081. 297 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carey L. O’Donnell Breakdown of academic impact, for papers by Taketoshi Yamano Breakdown of academic impact, for papers by Daniëlle Horst Breakdown of academic impact, for papers by Stephanie Könen‐Waisman Breakdown of academic impact, for papers by Nevil J. Singh Breakdown of academic impact, for papers by Yanal Murad Breakdown of academic impact, for papers by Tara L. Chapman Breakdown of academic impact, for papers by Christoph Schaefer Breakdown of academic impact, for papers by Amy Palin Breakdown of academic impact, for papers by Sungae Cho
Rankless by CCL
2026